Candriam S.C.A. Lowers Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Candriam S.C.A. decreased its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 90.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,254 shares of the company’s stock after selling 359,369 shares during the period. Candriam S.C.A.’s holdings in Centessa Pharmaceuticals were worth $1,440,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CNTA. Private Advisor Group LLC bought a new position in shares of Centessa Pharmaceuticals in the first quarter worth approximately $238,000. Y Intercept Hong Kong Ltd raised its holdings in Centessa Pharmaceuticals by 742.3% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 96,367 shares of the company’s stock worth $3,828,000 after acquiring an additional 84,926 shares during the last quarter. Pictet Asset Management Holding SA purchased a new position in Centessa Pharmaceuticals in the 1st quarter worth approximately $3,849,000. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $80,000. Finally, T. Rowe Price Investment Management Inc. lifted its position in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $40.50 on Wednesday. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.74 and a one year high of $40.56. The stock has a fifty day moving average of $40.00 and a 200 day moving average of $32.87. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The stock has a market cap of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Analysts Set New Price Targets

CNTA has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Finally, Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.